Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Esophagogastric Cancer
Xeloda(R) Combination Therapy in Esophagogastric Cancer Highlighted in New England Journal of Medicine
January 15th, 2008
Data published in this week's New England Journal of Medicine show that oral Xeloda(R) (capecitabine) and oxaliplatin in combination with epirubicin is a comparable alternative to infused fluorouracil (5-FU) and cisplatin with epirubicin in patients with previously untreated, advanced esophagogastric cancer. In the study, median survival time was longer and one-year survival was higher among patients taking the Xeloda, epirubicin and oxaliplatin combination compared to the standard treatment, epirubicin, cisplatin and 5- FU. Gastric and esophageal cancers are the second and sixth most common causes of cancer-related deaths worldwide, respectively,...
Source: Cancer Weekly (2008-01-15)
|
